MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Other Events

ME Staff 8-k
-
0
MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Other Events

MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS) Files An 8-K Other Events
Item 8.01. Other Events.

On December10, 2018, Marinus Pharmaceuticals,Inc. (the “Company”) conducted an investor conference call and webcast and issued a press release announcing results from its Phase 2 clinical trials in patients with postpartum depression. A copy of the slides presented during that call is filed as Exhibit99.1 to this Current Report on Form8-K and a copy of the press release is filed as Exhibit99.2 to this Current Report on Form8-K and are incorporated by reference in this Item 8.01 as though fully set forth herein.

Item 9.01. Financial Statements and Exhibits.


MARINUS PHARMACEUTICALS INC Exhibit
EX-99.1 2 a18-41111_3ex99d1.htm EX-99.1 Exhibit 99.1 Ganaxolone Data in PPD Studies December 10,…
To view the full exhibit click here

About MARINUS PHARMACEUTICALS,INC. (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.